Evidence map›Paper›PMID 31861689›Full record

ArticleMolecules (Basel, Switzerland)2019

Modeling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and Molecular Docking Study.

Edgar Márquez, José R Mora, Virginia Flores-Morales, Daniel Insuasty, Luis Calle

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Edgar MárquezGrupo de Investigación en Química y Biología, Departamento de Química y Biología, Universidad del Norte, Cra 51B, Km 5, vía Puerto Colombia, Barranquilla 081007, Colombia.
José R MoraGrupo de Química computacional y teórica (QCT-USFQ) & instituto de Simulación Computacional (ISC-USF), Departamento de Ingeniería Química, Colegio Politécnico de Ciencias e Ingeniería, Diego de Robles, y vía Interoceánica, Universidad San Francisco de Quito, Quito 170901, Ecuador.
Virginia Flores-MoralesLaboratorio de Síntesis Asimétrica y Bioenergética (LSAyB), Ingeniería Química (UACQ), Program of Doctorate in Sciences with orientation in Molecular Medicine, Academic Unit of Human Medicine and Health Sciences, Universidad Autónoma de Zacatecas, Campus XXI Km 6 Carr. Zac-Gdl Edificio 6, 98160 Zacatecas, Mexico.
Daniel InsuastyGrupo de Investigación en Química y Biología, Departamento de Química y Biología, Universidad del Norte, Cra 51B, Km 5, vía Puerto Colombia, Barranquilla 081007, Colombia.
Luis CalleInstituto de Biomedicina, Facultad de Medicina, Universidad Católica Santiago de Guayaquil, Guayaquil 09013493, Ecuador.
Universidad del Norte · COUniversidad Autónoma de Zacatecas "Francisco García Salinas" · MXUniversidad Católica de Santiago de Guayaquil · ECUniversidad San Francisco de Quito · EC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antileukemia cancer activity of organic compounds analogous to ellipticine representes a critical endpoint in the understanding of this dramatic disease. A molecular modeling simulation on a dataset of 23 compounds, all of which comply with Lipinski's rules and have a structure analogous to ellipticine, was performed using the quantitative structure activity relationship (QSAR) technique, followed by a detailed docking study on three different proteins significantly involved in this disease (PDB IDs: SYK, PI3K and BTK). As a result, a model with only four descriptors (HOMO, softness, AC1RABAMBID, and TS1KFABMID) was found to be robust enough for prediction of the antileukemia activity of the compounds studied in this work, with an R

Indexed as

Agammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsCell Line, TumorDensity Functional TheoryEllipticinesHumansLeukemiaModels, MolecularMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructurePhosphatidylinositol 3-KinasesQuantitative Structure-Activity RelationshipSyk KinaseAgammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsBTK protein, humanEllipticinesPhosphatidylinositol 3-KinasesSyk KinaseSYK protein, humancancerleukemiamolecular descriptorsmolecular modelingQSAR

Identifiers

PMID31861689
PMCPMC6982814
OpenAlexW2996235402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.